-- Anteris Technologies（ASX：AVR）周四向澳大利亚证券交易所提交的文件显示，该公司已通知v2vmedtech，将根据双方于2023年4月18日签署的出资及股权购买协议，停止向v2vmedtech提供额外的研发出资，并需向v2vmedtech支付40万澳元的违约金。 该公司表示，发出通知后，其不再有义务提供额外的研发出资。v2vmedtech的初始股东有权选择以下两种方式之一：以相当于其迄今为止出资总额的价格收购该公司在v2vmedtech的全部股权；或者将该公司的股权比例降低至上限规定的少数股权比例。 文件补充道，v2vmedtech尚未告知该公司其计划采取哪种方案。 该公司还表示，双方之间的研发协议将在支付40万澳元违约金后终止。该公司预计，终止协议不会对其财务状况或流动性产生重大不利影响。 该公司股价在最近的周四交易中上涨了3%。
Related Articles
Asia
Sanhua Intelligent Controls Q1 Profit Up 3%; Shares Rise 5%
Zhejiang Sanhua Intelligent Controls (SHE:002050) posted first-quarter attributable net profit of 927.6 million yuan, up 2.7% from 903.4 million yuan the previous year.Earnings per share declined to 0.22 yuan from 0.24 yuan, according to a Thursday filing with the Shenzhen bourse.Operating revenue climbed 1.4% year over year to 7.77 billion yuan from 7.67 billion yuan.Shares of the refrigeration and air-conditioning components maker were up 5% in recent trade.
$SHE:002050
Asia
Singapore's Total Employment Expands in Q1
Singapore's total employment grew by 5,000 during the first quarter of the year, compared to 2,300 a year earlier, marking the 18th consecutive quarter of job growth, according to preliminary data from the Ministry of Manpower released Thursday.Despite the year-on-year growth, employment was down from the 17,700 growth in the previous quarter, mainly due to broad-based weakening in the labor market.Overall, unemployment rates edged up to 2.1% in March, compared to 2.0% in December 2025.Retrenchments remained low at 1.5 per 1,000 employees in Q1, unchanged from Q4, 2025.The ministry expects labor market to remain tight and expand in the second quarter. However, the share of firms expecting to hire in the next three months fell to 44.6% in March, compared to 54.6% in February.
$^STI
Asia
Clarity Pharmaceuticals to Start Registrational Phase 3 Trial in Neuroendocrine Tumors After US FDA Meeting
Clarity Pharmaceuticals (ASX:CU6) will start a registrational phase 3 trial of copper-64-SARTATE in neuroendocrine tumors, following a successful end-of-phase meeting with the US Food and Drug Administration (FDA), according to a Thursday Australian bourse filing.The company plans to recruit around 70 participants for the trial.Clarity is also conducting recruitment for its registrational phase 3 positron emission tomography imaging trial of participants with high-risk prostate cancer prior to radical prostatectomy using copper-64-SAR-bisPSMA in the US and Australia, per the filing. It plans to recruit around 383 participants.The trial will assess the diagnostic performance of copper-64-SAR-bisPSMA positron emission tomography in detecting prostate cancer within the pelvic lymph nodes, the filing said.Clarity Pharmaceuticals' shares fell nearly 2% in recent trading on Thursday.
$ASX:CU6